Capturing and Implementing Business Rules & Decisions: The Intellectual Capital of Your Organization

AIRA Meeting – April 5, 2016

by Ronald G. Ross and Gladys S.W. Lam

Co-Founders & Principals, Business Rule Solutions, LLC BRSolutions.com

Executive Editor & Publisher, Business Rules Journal BRCommunity.com



about Ronald G. Ross



Ronald G. Ross is Co-Founder and Principal of Business Rule Solutions, LLC (*BRSolutions.com*). BRS provides consulting, training and methodology supporting business analysis, business rules, decision engineering, business vocabulary, and rule management. His popular seminars, the first on business rules (starting 1996), are the longest-running in the industry.

Mr. Ross co-develops $IPSpeak^{TM}$, BRS's landmark methodology, featuring numerous innovative techniques including the popular $DecisionSpeak^{TM}$, $TableSpeak^{TM}$ and $RuleSpeak^{SM}$ (free on RuleSpeak. com, now also in Spanish, German, Dutch, and Norwegian). These are the latest offerings in a 40-year career that has consistently featured creative, business-driven solutions.

Mr. Ross is also Executive Editor and regular columnist of *BRCommunity.com* and its flagship on-line publication, *Business Rules Journal*. Sponsored by BRS, BRCommunity.com is a non-commercial vertical community for professionals working in the field. Mr. Ross was formerly Editor of the *Data Base Newsletter* from 1977 to 1998.

Mr. Ross is recognized internationally as the 'father of business rules.' He has served as Chair of the annual **Business Rules & Decisions Forum Conference** since 1997, now part of the **BBC Conference**. He was a charter member of the Business Rules Group (BRG) in the 1980s, and an editor of the two landmark BRG papers, "The Business Motivation Model: Business Governance in a Volatile World" (2000) and the "Business Rules Manifesto" (2003). He is also active in OMG standards development for business rules and business models, including SBVR.

Mr. Ross is the author of ten professional books. His newest: *Business Rule Concepts: Getting to the Point of Knowledge* (2013), a 4th edition of his popular handbook, and *Building Business Solutions: Business Analysis with Business Rules*, 2nd edition, with Gladys S.W. Lam (2015). An earlier work, *The Business Rule Book* (1994, 1997), was the seminal work in the field. Mr. Ross received his M.S. in information science from Illinois Institute of Technology, and his B.A. from Rice University.

tweets: @Ronald_G_Ross



Gladys S.W. Lam is a world-renowned authority on applied business rule and decision techniques. She is Principal and Co-Founder of Business Rule Solutions, LLC (www.BRSolutions.com), the most recognized company world-wide in business rules and decision analysis. Ms. Lam is co-creator of IPSpeakTM, the BRS methodology. She is Co-Founder of BRCommunity.com, a vertical community for professionals and home of Business Rules Journal. She co-authored Business Rules, with Ronald G. Ross.

Ms. Lam is widely known for her lively, pragmatic style. Ms. Lam is an internationally recognized expert on business rules and decision techniques. She speaks worldwide at conferences and other professional events. She copresents interactive online seminars. She is also Executive Director of the Building Business Capability (BBC) Conference, which includes the Business Rules and Decisions Forum and is the official conference of the IIBA®.


Ms. Lam is a world-renowned expert on business project management, having managed numerous projects that focus on the large-scale capture, analysis and management of business rules and decisions. She works comfortably with senior executives providing insights and advice. She advises senior management of large companies on organizational issues and on business solutions to business problems. She is most effective with mentoring and training business analysts worldwide.

Ms. Lam is most recognized for her ability to identify the source of business issues, and for her effectiveness in developing pragmatic approaches to resolve them. She has gained a world-class reputation for fostering positive professional relationships with principals and support staff in projects.

Ms. Lam graduated from the University of British Columbia with a B.S. in Computer Science.

about Gladys Lam

Summer Palace, Beijing




© Business Rule Solutions, LLC

RMBY 400


RMBY 400

example: taxes




© Business Rule Solutions, LLC

example: mortgages



example: immunization



Administration of doses of a multidose vaccine using intervals that are shorter than recommended might be necessary in certain circumstances, such as impending international travel or when a person is behind schedule on vaccinations but needs rapid protection. In these situations, an accelerated schedule can be implemented using intervals between doses that are shorter than intervals recommended for routine vaccination. The accelerated or minimum intervals and ages for scheduling catch-up vaccinations are available at http://www.cdc.gov/vaccines. Vaccine doses should not be administered at intervals less than these minimum intervals or at an age that is younger than the minimum age.*

Before administering a vaccine dose, providers might need to verify that all previous doses were administered after the minimum age and in accordance with minimum intervals (Table 1). In clinical practice, vaccine doses occasionally are administered at intervals less than the minimum interval or at ages younger than the minimum age. Doses administered too close together or at too young an age can lead to a suboptimal immune response. However, administering a dose a few days earlier the minimum interval or age is unlikely to have a substantially negative effect on the immune response to that dose. Vaccine doses administered ≤ 4 days before the minimum interval or age are considered valid; however, local or state mandates might supersede this 4-day guideline.† (Day 1 is the day before the day that marks the minimum age or minimum interval for a vaccine.) Because of the unique schedule for rabies vaccine, the 4-day guideline does not apply to this vaccine (\int). Doses of any vaccine administered ≥ 5 days earlier than the minimum interval or age should not be counted as valid doses and should be repeated as age appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval (\int 1 be example, if the first and second doses of Haemophilus influenzae type b (Hib) were administered only 14 days apart, the second dose would be invalid and need to be repeated because the minimum interval from dose 1 to dose 2 is 4 weeks. The repeat dose should be administered ≥ 4 weeks after the invalid dose (in this case, the second). The repeat dose is counted as the valid second dose.

If the first dose in a series is given ≥5 days before the recommended minimum age, the dose should be repeated on or after the date when the child reaches at least the minimum age. If the vaccine is a live vaccine, ensuring that a minimum interval of 28 days has elapsed from the invalid dose is recommended. For example, if the first dose of varicella vaccine were inadvertently administered at age 10 months, the repeat dose would be administered no earlier than the child's first birthday (the minimum age for the first dose). If the first dose of varicella vaccine were administered at age 11 months and 2 weeks, the repeat dose should be administered no earlier than 4 weeks thereafter, which would occur after the first birthday.

Certain vaccines (e.g., adult tetanus and diphtheria toxoids [Td], pediatric diphtheria and tetanus toxoids [DT]; and tetanus toxoid) produce increased rates of local or cyclomic reactions in cortain recipients when administered more frequently than recommended (6.7). Careful record keeping, maintenance of patient

© Business Rule Solutions, LLC



No jet-powered cars.

me

No car is allowed if it has a peacock on the top.

No peacock is allowed if it has a car at the bottom.

Gene Weng

A vehicle must not carry a Christmas tree on its roof if it's on fire.

Casper Yeow

No campfires on a car roof.

J John Jones

No car explosions allowed in the area.

Johannes van Schalkwyk

to be discussed

- what is a business rule
- why business rules
- audience participation
- case study
- conclusions

what is a business rule

Provide a feature to handle electronic funds transfer.

Provide a feature to handle electronic funds transfer.

... requirement

Customer provides account id. System displays account.

Customer provides account id. System displays account.

... use case statements

If the overdrawn flag is set to 'yes', reject transaction.

If the overdrawn flag is set to 'yes', reject transaction.

... system if/then statement

definition

business rule: criterion used in business operations to ...

- guide behavior
- make decisions

requirement

Provide a feature to handle electronic funds transfer.

business rule

Every employee expense reimbursement must be processed through electronic funds transfer.

use case statement

Customer provides account id. System displays account.

business rule

A customer must have a valid account.

system if/then statement

If the overdrawn flag is set to 'yes', reject transaction.

business rules

- 1. An account must not be overdrawn.
- 2. An account may be considered overdrawn only if cash withdrawal is greater than the current balance of the account.

business rule statement

A vaccine dose administered must be considered an allowable vaccine if all the following are true:

- The vaccine type of the vaccine dose administered is one of the allowable vaccine types.
- The date administered is on or later than the allowable vaccine type begin age date.
- The date administered is earlier than the allowable vaccine type end age date.

business rule

The vaccine lot number must be reported for every vaccination event.

definitions

Vaccination Event: administration of one Vaccine to a Patient

Vaccination Encounter: an interaction between a Provider and Patient resulting in one or more Vaccination Events

Provider: a medical practitioner (e.g., physician, nurse) who administers an immunization – i.e., conducts a Vaccination Event

Patient:

Vaccine:

Vaccine Lot Number:

subject vocabulary

Can a vaccine dose administered be evaluated and why?

Dose Condition Indicated?

		Yes	No
Vaccination Expired?	Yes	Vaccine dose administered cannot be evaluated	Vaccine dose administered cannot be evaluated
	No	Vaccine dose administered cannot be evaluated	Vaccine dose administered can be evaluated

Definition:

Vaccination Expired means Vaccination Date > Lot Expiration Date

decision tables

why business rules

1. communication

are we communicating?



"The single biggest problem in communication is the illusion that it has taken place."

George Bernard Shaw

should finish date be actual finish date or forecast finish date?

	Name	Rule Statement	Status
8	Show all	contains finish date	Show all
2	Series 001	A patient series must be considered completable if the finish date it less than the maximum age date of the last target dose.	Proposed
2	Series 002	A complete patient series must be considered to be the earliest completing if the actual finish date it before the actual finish date for all other candidate patient series.	Proposed
2	Series 004	The actual finish date of a complete patient series must be the latest date administered or a vaccine dose administered with an evaluation status "valid."	Proposed
2	Series 008	A patient series not be considered to finish earliest if the patient series can be completed and the forecast finish date is earlier than the forecast finish date in all other candidate patient series.	Proposed

© Business Rule Solutions, LLC

better RFPs

Implementers often receive poorly structured content, producing significant problems in interpretation and completeness.



"We elicit business rules, express them in RuleSpeak®, and include them in RFPs. Implementers love it."

Paul Franz


Reference: RuleSpeak® 3.0 (free download) http://www.brsolutions.com/b_ipspeakprimers.php

Business rules are about business communication ... people communicating with people, often displaced in time, place & function.

2. knowledge retention

"More than 60% of all our staff who know our tribal knowledge will retire in the next 3 years."

manager, insurance company



Lost your developers and you're clueless how a business capability works?

You're not managing the business rules.




3. knowing why


the WHY challenge




© Business Rule Solutions, LLC

Why was my mortgage application rejected?





Reference: *DecisionSpeak* – free on http://www.brsolutions.com/b ipspeakprimers.php



A WHY button should be part of every business solution.



4. compliance

Compliance people don't really want to know HOW you do what you do.

They want to know WHY you get the results you do.

"We have finally found an approach that really works: compliance = interpretation & traceability of business rules."

compliance manager, financial company



audience participation

No driving without a license.

These items may or may not be available at all times, and sometimes not at all and other times all the time.

Menu Item in Restaurant *Ft. Bragg, NC*

... not inscrutable!

Regardless of anything to the contrary in this booklet, if your medical insurance terminates for any reason including death, you ... may elect within 30 days ... to continue such medical insurance.

From the booklet "Group Insurance for I-14 Employees" Consolidated Group Trust, The Hartford

... not impossible!

A team must have a manager.

Ask: What does "to have" mean?

be managed by a manager?


be sponsored by a manager?

be approved by a manager?

A team must have a manager.

revised rule:

A team must be managed by a manager.



ask about ambiguity



An order must not be shipped if the outstanding balance exceeds credit authorization.

Ask: Outstanding balance of what?

border? ...customer? ...account? ...shipment?

Ask: Credit authorization of what?

order? ...customer? ...account? ...shipment?



An order must not be shipped if the outstanding balance exceeds credit authorization.

missing meanings:

customer places order customer has credit authorization customer holds account account has outstanding balance

revised rule:

An order must not be shipped if the outstanding balance of the account held by the customer that placed the order exceeds the credit authorization of the customer.


ask about ambiguity



An order must not be shipped if the outstanding balance exceeds credit authorization.

revised rule:

An order must not be shipped if the outstanding balance of the account held by the customer that placed the order exceeds the credit authorization of the customer.



ask about ambiguity



A customer may make a withdrawal only if their account is active.

Ask: What about pre-authorized third parties?

What about the bank itself?

What about automated payment system?



A customer may make a withdrawal only if their account is active.

revised rule:

A withdrawal for an account may be made only if the account is active.



A project must be considered active if it has manager, a budget, or a sponsor.

Ask: How many?

♦ At least one?

♦ Exactly one?

What if the threshold changes to "any 2 of the 3"?



A project must be considered active if it has manager, a budget, or a sponsor.

revised rule:

A project must be considered active if at least one of the following is true:

- It has a manager.
- It has a budget.
- It has a sponsor.

case study

immunization rules for children



translating ACIP recommendations

Advisory Committee on Immunization Practices (ACIP)

Clinical Immunization Recommendations





CDS Engine

specification

Morbidity and Mortality Weekly Report (MMWR)

Recommend < 40 ▼ Tweet < 4
</p> Share

MMWR

General Recommendations on Immunization

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Please note: An erratum has been published for this article. To view the erratum, please click here.

Recommendations and Reports

January 28, 2011 / 60(RR02);1-60

Prepared by Andrew T. Kroger, MD1 Ciro V. Sumaya, MD2 Larry K. Pickering, MD1 William L. Atkinson, MD1

1 National Center for Immunization and Respiratory Diseases 2Texas A&M Health Science Center, College Station, Texas

The material in this report originated in the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director.

Corresponding preparer: Andrew Kroger, MD, National Center for Immunization and Respiratory Diseases, 1600 Clifton Rd., MS E-52, Atlanta, GA 30333. Telephone: 404-639-1958; Fax: 404-639-8828; E-mail: aok2@cdc.gov.

Summary

This report is a revision of the General Recommendations on Immunization and updates the 2006 statement by the Advisory Committee on Immunization Practices (ACIP) (CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2006;55[No. RR-15]). The report also includes revised content from previous ACIP recommendations on the following topics: adult vaccination (CDC, Update on adult immunization recommendations of the immunization practices Advisory Committee [ACIP]. MMWR 1991;40[No. RR-12]); the assessment and feedback strategy to increase vaccination rates (CDC, Recommendations of the Advisory Committee on Immunization Practices; programmatic strategies to increase vaccination rates---assessment and feedback of provider-based vaccination coverage information. MMWR 1996;45:219--20); linkage of vaccination services and those of the Supplemental Nutrition Program for Women, Infants, and Children (WIC program) (CDC. Recommendations of the Advisory Committee on © β_{11} Immunization Practices: programmatic strategies to increase vaccination coverage by age 2 years---linkage of vaccination and WIC services. MMWR 1996;45:217--8); adolescent immunization (CDC. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the

Poliomyelitis Prevention in the United States

Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Summary

These recommendations of the Advisory Committee on Immunization Practices (ACIP) for poliomyelitis prevention replace those issued in 1997. As of January 1, 2000, ACIP recommends exclusive use of inactivated poliovirus vaccine (IPV) for routine childhood polio vaccination in the United States. All children should receive four doses of IPV at ages 2, 4, and 6--18 months and 4--6 years. Oral poliovirus vaccine (OPV) should be used only in certain circumstances, which are detailed in these recommendations. Since 1979, the only indigenous cases of polio reported in the United States have been associated with the use of the live OPV. Until recently, the benefits of OPV use (i.e., intestinal immunity, secondary spread) outweighed the risk for vaccine-associated paralytic poliomyelitis (VAPP) (i.e., one case among 2.4 million vaccine doses distributed). In 1997, to decrease the risk for VAPP but maintain the benefits of OPV, ACIP recommended replacing the all-OPV schedule with a sequential schedule of IPV followed by OPV. Since 1997, the global polio eradication initiative has progressed rapidly, and the likelihood of poliovirus importation into the United States has decreased substantially. In addition, the sequential schedule has been well accepted. No declines in childhood immunization coverage were observed, despite the need for additional injections. On the basis of these data, ACIP recommended on June 17, 1999, an all-IPV schedule for routine childhood polio vaccination in the United States to eliminate the risk for VAPP. ACIP reaffirms its support for the global polio eradication initiative and the use of OPV as the only vaccine recommended to eradicate polio from the remaining countries where polio is endemic.



Poliomyelitis Prevention in the United States

Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Summary

These recommendations of the Advisory Committee on Immunization Practices (ACIP) for polionyelitis prevention replace those issued in 1997. As of January 1, 2000, ACIP recommends exclusive use of inactivated poliovirus vaccine (IPV) for routine childhood polio vaccination in the United States. All children should receive four doses of IPV at ages 2, 4, and 6–18 months and 4–6 years. Oral voliovirus vaccine (OPV) should be used only in certain circumstances, which are detailed in these recommendations. Since 1979, the lands was cases of polio reported in the United States have been associated with the use of the live OPV. Until recently, the benefits of OPV use (i.e., intestinal immunity, secondary spread) outweighed the risk for vaccine-associated paralytic polionyelitis (IAPP) (i.e., one case among 2.4 m. lion vaccine doses distributed). In 1997, to decrease the risk for vaccine-associated paralytic polionyelitis (IAPP) in the commended replacing via all-OPV schedule with a sequential schedule of IPV followed by OPV. Since 1997, the global polio eradication initiative has proverseed repulsely, and the likelihood of poliovirus importation into the United States decreased substantially.

initiative has progressed rap addition, the sequential sche for additional injections. On vaccination in the United Sta use of OPV as the only vacci

All children should receive four doses of IPV at ages 2, 4, and 6--18 months and 4--6 years. Oral poliovirus vaccine (OPV) should be used only in certain cir cumstances, which are detailed in these recommendations.



- 2 and 4 months or years?
- up to, or up to and including (through),18 months and 6 years
- vaccination at 2 or 4 months? what about +/- 1 day? +/- 5 days? +/- 30 days? what is the threshold?



nature of sources

- increase precision
- eliminate inconsistency
- drill down on decision logic
- fill gaps

Poliomyelitis Prevention in the United States


Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Summary

These recommendations of the Advisory Committee on Immunization Practices (ACIP) for poliomyelitis prevention replace those issued in 1997. As of January 1, 2000, ACIP recommends exclusive use of inactivated poliovirus vaccine (IPV) for routine childhood polio vaccination in the United States. All children should receive four doses of IPV at ages 2, 4, and 6--18 months and 4--6 years. Oral poliovirus vaccine (OPV) should be used only in certain circumstances, which are detailed in these recommendations. Since 1979, t s cases of polio reported in the United States have been associated with the use of the live OPV. Until recently, the benefits of OPV use (... intestinal immunity, secondary spread) outweighed the risk for vaccine-associated paralytic poliomyelitis (VAPP) (i.e., one case among 2.4 m. Vion vaccine doses distributed). In 1997, to decrease the risk for VAPP but maintain the benefits of OPV, ACIP recommended replacing 🖓 all-OPV schedule with a sequential schedule of IPV followed by OPV. Since 1997, the global polio eradication


initiative has progressed rapidly, and the likelihood of poliovirus importation into the United States has decreased substantially. In for additional injections. On vaccination in the United St use of OPV as the only vacci

All children should receive four doses of IPV at ages 2, 4, and 6--18 months and 4--6 years. Oral poliovirus vaccine (OPV) should be used only in certain circumstances, which are detailed in these recommendations.




date ranges of

- o through 2 months
- 2 months + 1 day through 4 months
- 6 months through 18 months
- 4 years through 6 years






concept model (structured business vocabulary)




Antigen	a foreign (non-self) substance which can cause an immune response
Antigen Series	one possible path to achieve presumed immunity against a disease
Antigen Series Dose	the measured quantity of a medicine or other therapeutic agent to be taken at one time or in a period of time
Antigen Series Dose given to Patient	an Antigen Series Dose given to a patient
Antigen Series given to Patient	an Antigen Series given to a patient


process model



Q-Chart



Q-COE



decision table

considerations			
Is the vaccine type of the vaccine dose administered one of the allowable vaccine types?	yes	no	yes
Allowable vaccine type begin age date ≤ date administered < allowable vaccine type end age date?	yes	-	no
outcomes	The patient received an allowable vaccine.	The patient did not receive an allowable vaccine.	The patient did not receive an allowable vaccine.

business rule statements


A vaccine dose administered must be considered an allowable vaccine if all the following are true:

- The vaccine type of the vaccine dose administered is one of the allowable vaccine types.
- The date administered is on or later than the allowable vaccine type begin age date.
- The date administered is earlier than the allowable vaccine type end age date.


business rule groups

Na	ame	Rule Statement
1 =	Overarching Date Rules	
2	🛸 BR 341	The computed date of adding any number of years to an existing date must be calculated by incrementing the year while holding the month and day constant.
3	🥦 BR 342	The computed date of adding any number of months to an existing date must be calculated lincrementing the month (and year, if necessary) while holding the day constant.
4	№ BR 343	The computed date of adding any number of weeks or days to an existing date must be calculated by adding the total days to the existing date.
5	% BR 344	The computed date of subtracting any number of days from an existing date must be calculated by subtracting the total days from the existing date.
6	· 🥦 BR 345	A computed date which is not a real date must be moved forward to first day of the next mon
7 🛨	Min/Max Date Rules	
13 📮	🖲 Interval Date Rules	
14	- ' 🥦 BR 361	The patient's Absolute Minimum Interval Date must be calculated as the patient's Reference Dose Date plus the Absolute Minimum Interval.
15	- ' № BR 362	The patient's Minimum Interval Date must be calculated as the patient's Reference Dose Da plus the Minimum Interval.
16	- ' № BR 363	The patient's earliest recommended interval date must be calculated as the patient's date of birth plus the Earliest Recommended Interval.
17	· ' № BR 364	The patient's Latest Recommended Interval date must be calculated as the patient's date of birth plus the Latest Recommended Interval.
18	- № BR 365	The patient's Latest Minimum Interval Date must be the Latest Date of all calculated Minimu Interval Dates for a given Target Dose.
	🖲 Skip Target Dose Date Rules	
21 🖃	Substitute Target Dose Date Rules	
22	№ BR 352	The patient's First Dose Begin Age Date must be calculated as the patient's Date of Birth plus Substitute Dose First Dose Begin Age.
23	- 🥦 BR 353	The patient's First Dose End Age Date must be calculated as the patient's Date of Birth plus Substitute Dose First Dose End Age.

step 2: the destination




management






vision

business terms




business rules




business rules


minimum age is used to calculate minimum age date for a patient



decision tables



decision tables



publication



CLINICAL DECISION SUPPORT FOR IMMUNIZATION (CDSI): LOGIC SPECIFICATION FOR ACIP RECOMMENDATIONS

National Center for Immunization and Respiratory Disease (NCIRD)

Immunization Information Systems Support Branch (IISSB)

Version 2.1

January 4, 2016

Logic Specification

- clinical decision aid
- interprets ACIP recommendations for IIS community
- implementationindependent
- published on CDC website

Logic Specification for ACIP Recommendations v2.1

Page 1 of 120 Last Reviewed Feb 2016

sample Logic Specification pages

3. TARGET DOSE

Target dose is a term used often in the Logic Specification document. A target dose is a patient-specific dose required to satisfy the recommendations of ACIP. Until a target dose is satisfied, the patient is not allowed to move to the next target dose in the patient series. The patient remains on the "unsatisfied" target dose until the patient has a "valid" vaccine dose administered that satisfies the target dose. A target dose is also allowed to be skipped however this situation isn't the common path and not immediately discussed here. Details on skipping target doses can be found in chapters 4 and 5.

This concept can be seen graphically below in figure 3-1. For simplicity in this hypothetical patient series, the target doses are defined only by the minimum age. The target doses have minimum ages of 0 days, 2 months, and 6 months. These are the minimum ages allowed by this patient series. The patient must have vaccine doses administered on or after these minimum ages to be considered valid. A valid vaccine dose administered will satisfy a target dose and allow movement to the next target dose. A vaccine dose administered which is anything but valid does not satisfy a target dose and does not allow movement to the next target dose.

This can be seen in figure 3-1 by looking at *target dose 2* and vaccine doses administered *dose 2* and *dose 3*. Dose 2 was administered too early and resulted in the evaluation status "not valid." A not valid vaccine dose administered means the target dose was not satisfied and must be repeated. Dose 3 was given at an appropriate age which resulted in the evaluation status "valid" and satisfied the goals of target dose 2. This allows movement to target dose 3 which is subsequently satisfied by vaccine dose administered *dose 4*.

While not shown on this graphic, there is also a status which tracks the patient's progress towards completion of a patient series. In this example, the patient series status is "not complete" for the first three vaccine doses administered. The patient series status is changed to "complete" once the fourth vaccine dose administered satisfies the third target dose which completes the patient series.

The following process model, attribute table and decision table are used to evaluate age at administration.



FIGURE 4 - 1 EVALUATE AGE PROCESS MODEL

TABLE 4 - 1 AGE ATTRIBUTES

Attribute Type	Attribute Name	Assumed Value if empty
Vaccine dose administered	Date Administered	-
Calculated date (CALCDTAGE-1)	Maximum Age Date	12/31/2999
Calculated date (CALCDTAGE-4)	Minimum Age Date	01/01/1900
Calculated date (CALCDTAGE-5)	Absolute Minimum Age Date	01/01/1900

TABLE 4 - 2 WAS THE VACCINE DOSE ADMINISTERED AT A VALID AGE?

CONDITIONS Is the Date administered < absolute minimum age date?	RULES						
	Yes	No	No	No	No	No	
Is the Absolute minimum age date ≤ date administered < minimum age date?	No	Yes	Yes	Yes	No	No	
Is the Minimum age date ≤ date administered < maximum age date?	No	No	No	No	Yes	No	
Is the Date administered <u>> maximum age date?</u>	No	No	No	No	No	Yes	
Is this the first target dose?	-	No	No	Yes	-	-	
Is the evaluation status of the previous vaccine dose administered "not valid" due to age or interval recommendations?	-	Yes	No	-	-	-	
OUTCOMES	No. The vaccine dose administered was not administered at a valid age. Evaluation reason is "too young."	No. The vaccine dose administered was not administered at a valid age. Evaluation reason is "too young."	Yes. The vaccine dose administered was administered at a valid age. Evaluation reason is "grace period."	Yes. The vaccine dose administered was administered at a valid age. Evaluation reason is "grace period."	Yes. The vaccine dose administered was administered at a valid age.	No. The vaccine dose was administered after the maximum ag and is extraneou Evaluation reaso is "too old."	

Spacing of Multiple Doses of the Same Antigen

Vaccination providers should adhere as closely as possible to recommended vaccination schedules (Table 1). Administration at Vaccination providers about adhere as closely as possible to recommended vaccination schedules (Table 3). Amministration in recommended gas and in accordance with recommended value intervals better on consistent of closes of a multidose vaccine using intervals that are consistent of closes of a multidose vaccine using intervals that are consistent of consistent of the c

internals recommenda for rotune vaccination, i not acceptance of maintaining and internal recommendation of the age that is upon plane and one acceptance of maintaining age that is upon plane acceptance and maintaining age. The acceptance administered after the minimum age and in accordance with minimum intervals (Table 1) in failured practice, vaccine doses occasionally are administered after the minimum age. can lead to a suboptimal immune response. However, administering a dose a few days earlier the minimum interval or age is unlikely to here a substantially negative effect on the immune response to that does. Vaccine doses administered 34 days before the minimum interval or age are considered valid, however, local or state mandates might supervised this 4-day guideline; "((par) 4 day before

the day that marks the minimum age or minimum interval for a vaccine.) Because of the unique schedule for rabies vaccine, the 4-day guideline does not apply to this vaccine.) Doese of any vaccine administered 25 days earlier than the minimum interval or age should not be counted as valid docese and should be repeated as age appropriate. The repeat does should be packed after the invalid dose by the recommended minimum interval (Table 1). For example, if the first and second doses of Haemophius influenzae type b (Hib) were administered only 14 days apart, the second dose would be invalid and need to be repeated because the minimum interval from dose 1 to dose 2 is 4 weeks. The repeat dose should be administered >4 weeks after the invalid dose (in this case, the second) The repeat dose in outset as the valid second dose.

If the first dose in a series is given 25 days before the recommended minimum age, the dose should be repeated on or after the date

when the child reaches at least the minimum age. If the veccine is a live veccine, ensuring that a minimum interval of 28 days has elapsed from the invalid dose is recommended. For example, if the first dose of varicella vaccine were inadvertently administered at age 10 months, the repeat dose would be administered no earlier than the child's first birthday (the minimum age for the first dose). If the first dose of varicted vaccine were administered at age 11 months and 2 weeks, the repeat dose should be administered no earlier than 4 weeks thereafter, which would occur after the first birthday.


Certain vaccines (e.g., adult telenaus and dipthrins toxoids [Td], pediatric dipthrenia and telanus toxoids [DT], and telanus toxoid produce increased rates of local or systemic reactions in certain recipirate when administered more frequently than recommended (6.7). Careful record keeping, maintenance of pelidernic histories, use of immunization information systems (IISs.), and adherence to recommended schedules can decrease the incidence of such reactions without adversely affecting immunity.



working together







The following process model, attribute table and decision table are used to evaluate age at administration. FIGURE 4 - 1 EVALUATE AGE PROCESS MODE TABLE 4 - 1 AGE ATTRIBUTES

Attribute Type	Attribute Name	Assumed Value if empty
	Date Administered	-
Calculated date (CALCDTAGE-1)	Maximum Age Date	12/31/2999
Calculated date (CALCDTAGE-4)	Minimum Age Date	01/01/1900
Calculated date (CALCDTAGE-5)	Absolute Minimum Age Date	01/01/1900

TABLE 4 - 2 WAS THE VACCINE DOSE ADMINISTERED AT A VALID AGE?

CONDITIONS Is the Date administered < absolute minimum age date?	RULES					
	Yes	No	No	No	No	No
Is the Absolute minimum age date ≤ date administered < minimum age date?	No	Yes	Yes	Yes	No	No
Is the Minimum age date ≤ date administered < maximum age date?	No	No	No	No	Yes	No
Is the Date administered > maximum age date?	No	No	No	No	No	Yes
Is this the first target dose?		No	No	Yes	-	
Is the evaluation status of the previous vaccine dose administered "not valid" due to age or interval recommendations?		Yes	No	•		
OUTCOMES	No. The vaccine dose administered was not administered at a valid age. Evaluation reason is "too young."	No. The vaccine dose administered was not administered at a valid age. Evaluation reason is "too young."	Yes. The vaccine dose administered was administered at a valid age. Evaluation reason is "grace period."	Yes. The vaccine dose administered was administered at a valid age. Evaluation reason is "grace period."	Yes. The vaccine dose administered was administered at a valid age.	No. The vaccine dose was administered aff the maximum as and is extraneous Evaluation reason is "too old."

Communication

unambiguous, internally consistent specification

Knowledge Retention

rule management within repository

Knowing Why


 practicable, implementationindependent specification

Compliance

 comprehensive traceability of interpretations


goal for know-how in a knowledge economy






IT technology

the same complete, intelligible, unambiguous, deployable meaning for each audience







Building Business Solutions

Business Analysis with Business Rules

2nd edition, 2015

Business Rule Concepts

Getting to the Point of Knowledge

4th edition, 2013

Primer Trio

Decision Analysis
Decision Tables
RuleSpeak® 3.0

brsolutions.com (free)

http://www.brsolutions.com/publications

BRS instructor-led online training series ...

- June 7-9, 2016 ... Working with Business Rules: Capture, Specification, Analysis & Management
- Oct 4-6, 2016 ... Business Analysis with Business
 Rules: From Strategy to Requirements



http://www.brsolutions.com/training

references

- 2007 OMG Semantics of Business Vocabulary and Business Rules (SBVR) standard
- 2000 BRG Business Motivation Model (BMM)
 www.businessrulesgroup.org/second_paper/BRG-BMM.pdf
- 2002 Business Rules Manifesto (16+ languages)
 www.businessrulesgroup.org/brmanifesto.htm
- 1997 2016 Business Rules & Decisions Forum conference, Oct. 31 Nov 4, Las Vegas
- 2000 2016 www.BRCommunity.com



request 30 minutes with us!



Ronald G. Ross Business Rule Solutions, LLC <u>Rross@BRSolutions.com</u> @Ronald_G_Ross



thank you!



www.BRSolutions.com



Gladys S. W. Lam Business Rule Solutions, LLC <u>Glam@BRSolutions.com</u> @GladysLam